Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns

Genentech’s proposal to run a new confirmatory trial of Avastin (bevacizumab) while the first-line metastatic breast cancer claim remains on label was undermined by practical considerations raised at the June 28-29 hearing on CDER's proposal to withdraw the indication.